Newswise — A press briefing at the 3rd International Symposium on Focused Ultrasound will introduce media to an innovative alternative to surgery – focused ultrasound technology – and the medical areas where it is being studied, including cancer, epilepsy and stroke.
Principle Investigator Jeff Elias, M.D., Associate Professor of Neurological Surgery and Neurology at the University of Virginia, will announce his new clinical trial investigating the use of focused ultrasound technology in treating patients with tremor-dominant Parkinson’s disease (TDPD) who exhibit significant disability despite medical treatment. Focused ultrasound technology offers the potential to treat medication-refractory TDPD patients with a completely noninvasive procedure, a significant improvement over the current standard of care, which requires the surgical implementation of a pacemaker in the brain.
The study will begin treating its first TDPD patients in mid-October. The trial is an FDA-approved double-blinded protocol study where 30 patients are randomly assigned to either treatment or control groups, and followed for a year to evaluate its effectiveness. The procedure is noninvasive – no skull incisions will be made – and performed without anesthesia. Patients will remain awake and communicative throughout the process. Dr. Elias will provide an overview of the study, the procedure and how it is performed and the evaluation process.
Also speaking will be clinicians in other medical fields, who will describe how the technology is being studied and applied in their areas of specialty. Each expert will provide more specific information around how this procedure works, and the stage and progress of their studies. A Q&A will be held after the presentation and all experts will be available following the press briefing for interviews.
Source: News wise.com